▲ Peaking
Business
uniQure stock crashes as Huntington’s gene therapy data weaken
uniQure stock plunges following disappointing trial data for its Huntington’s disease gene therapy.
Huntington
2 trends tracked about this subject — the full history, oldest to newest below.
◼ Archived
Health
🔮 fades
Restoring cortical disinhibition improves Huntington’s disease phenotypes
5 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.